Sandbox Rim: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
{|
<table class="wikitable">
|colspan=2|Outpatient
<tr class="v-firstrow"><th>Scenario </th><th> Recommendation</th></tr>
|-
<tr><td>Outpatient: Previously healthy and no use of antimicrobials within the previous 3 months </td><td> A macrolide <br> Doxycyline</td></tr>
|Previously healthy and no use of antimicrobials within the previous 3 months || A macrolide <br> Doxycyline
<tr><td>Outpatient: Presence of comorbidities such as chronic heart, lung, liver or renal disease; diabetes mellitus; alcoholism; malignancies; asplenia; immunosuppressing conditions or use of immunosuppressing drugs</td><td>A fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin [750 mg])<br>
|-
A b-lactam plus a macrolide</td></tr>
|Presence of comorbidities such as chronic heart, lung, liver or renal disease; diabetes mellitus; alcoholism; malignancies; asplenia; immunosuppressing conditions or use of immunosuppressing drugs||A fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin [750 mg])<br>
<tr><td>Outpatient: Use of antimicrobials within the last 3 months</td><td> An alternative from a different class should be selected:<br>
A b-lactam plus a macrolide
A fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin [750 mg])<br>
|-
A b-lactam plus a macrolide</td></tr>
|Use of antimicrobials within the last 3 months|| An alternative from a different class should be selected:<br>
<tr><td>Outpatient: In regions with a high rate (125%) of infection with high-level (MIC 16 mg/mL) macrolide-resistant Streptococcus pneumoniae</td><td>A fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin [750 mg])<br>
A fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin [750 mg]) (strong recommendation; level I evidence)<br>
A b-lactam plus a macrolide</td></tr>
A b-lactam plus a macrolide (strong recommendation; level I evidence)
<tr><td>Inpatient general medical ward </td><td> A respiratory fluoroquinolone<br>A b-lactam plus a macrolide</td></tr>
|-
<tr><td>Inpatient ICU </td><td> A b-lactam (cefotaxime, ceftriaxone, or ampicillin-sulbactam) plus azithromycin<br> A b-lactam (cefotaxime, ceftriaxone, or ampicillin-sulbactam) plus a fluoroquinolone
|In regions with a high rate (125%) of infection with high-level (MIC 16 mg/mL) macrolide-resistant Streptococcus pneumoniae||A fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin [750 mg])<br>
<br> For penicillin-allergic patients: a respiratory fluoroquinolone and aztreonam</td></tr>
A b-lactam plus a macrolide
<tr><td>Outpatient: Concern about pseudomonas</td><td>An antipneumococcal, antipseudomonal b-lactam (piperacillintazobactam, cefepime, imipenem, or meropenem) plus either ciprofloxacin or levofloxacin (750 mg)
|-
|Inpatient general medical ward || A respiratory fluoroquinolone<br>A b-lactam plus a macrolide
|
|-
| Inpatient ICU || A b-lactam (cefotaxime, ceftriaxone, or ampicillin-sulbactam) plus azithromycin<br> A b-lactam (cefotaxime, ceftriaxone, or ampicillin-sulbactam) plus a fluoroquinolone
<br> For penicillin-allergic patients: a respiratory fluoroquinolone and aztreonam
|-
|Concern about pseudomonas||An antipneumococcal, antipseudomonal b-lactam (piperacillintazobactam, cefepime, imipenem, or meropenem) plus either ciprofloxacin or levofloxacin (750 mg)
<br> B-lactam plus an aminoglycoside and azithromycin
<br> B-lactam plus an aminoglycoside and azithromycin
<br>B-lactam plus an aminoglycoside and an antipneumococcal fluoroquinolone<br>
<br>B-lactam plus an aminoglycoside and an antipneumococcal fluoroquinolone<br>
For penicillin-allergic patients, substitute aztreonam for above b-lactam
For penicillin-allergic patients, substitute aztreonam for above b-lactam</td></tr>
|-
<tr><td>Concern about community acquired MRSA </td><td> Add vancomycin or linezolid</td></tr>
|Concern about community acquired MRSA || Add vancomycin or linezolid
|}

Revision as of 19:26, 19 February 2015

Scenario Recommendation
Outpatient: Previously healthy and no use of antimicrobials within the previous 3 months A macrolide
Doxycyline
Outpatient: Presence of comorbidities such as chronic heart, lung, liver or renal disease; diabetes mellitus; alcoholism; malignancies; asplenia; immunosuppressing conditions or use of immunosuppressing drugsA fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin [750 mg])
A b-lactam plus a macrolide
Outpatient: Use of antimicrobials within the last 3 months An alternative from a different class should be selected:

A fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin [750 mg])

A b-lactam plus a macrolide
Outpatient: In regions with a high rate (125%) of infection with high-level (MIC 16 mg/mL) macrolide-resistant Streptococcus pneumoniaeA fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin [750 mg])
A b-lactam plus a macrolide
Inpatient general medical ward A respiratory fluoroquinolone
A b-lactam plus a macrolide
Inpatient ICU A b-lactam (cefotaxime, ceftriaxone, or ampicillin-sulbactam) plus azithromycin
A b-lactam (cefotaxime, ceftriaxone, or ampicillin-sulbactam) plus a fluoroquinolone
For penicillin-allergic patients: a respiratory fluoroquinolone and aztreonam
Outpatient: Concern about pseudomonasAn antipneumococcal, antipseudomonal b-lactam (piperacillintazobactam, cefepime, imipenem, or meropenem) plus either ciprofloxacin or levofloxacin (750 mg)


B-lactam plus an aminoglycoside and azithromycin
B-lactam plus an aminoglycoside and an antipneumococcal fluoroquinolone

For penicillin-allergic patients, substitute aztreonam for above b-lactam
Concern about community acquired MRSA Add vancomycin or linezolid